Neurologia最新文献

{"title":"Manifestaciones neurológicas asociadas a la vacuna contra COVID-19","authors":"R. Alonso Castillo,&nbsp;J.C. Martínez Castrillo","doi":"10.1016/j.nrl.2022.09.005","DOIUrl":"10.1016/j.nrl.2022.09.005","url":null,"abstract":"<div><h3>Introduction</h3><div>Coronavirus disease 2019 (COVID-19) has spread rapidly, giving rise to a pandemic, causing significant morbidity and mortality. In this context, many vaccines have emerged to try to deal with this disease.</div></div><div><h3>Objective</h3><div>To review the reported cases of neurological manifestations after the application of COVID-19 vaccines, describing clinical, analytical and neuroimaging findings and health outcomes.</div></div><div><h3>Methods</h3><div>We carried out a review through bibliographic searches in PubMed.</div></div><div><h3>Results</h3><div>We found 86 articles, including 13,809 patients with a wide spectrum of neurological manifestations temporally associated with COVID-19 vaccination. Most occurred in women (63.89%), with a median age of 50 years. The most frequently reported adverse events were Bell's palsy 4936/13809 (35.7%), headache (4067/13809), cerebrovascular events 2412/13809 (17.47%), Guillain-Barré syndrome 868/13809 (6.28%), central nervous system demyelination 258/13809 (1.86%) and functional neurological disorder 398/13809 (2.88%). Most of the published cases occurred in temporal association with the Pfizer vaccine (BNT162b2), followed by the AstraZeneca vaccine (ChAdOX1 nCoV-19).</div></div><div><h3>Conclusions</h3><div>It is not possible to establish a causal relationship between these adverse events and COVID-19 vaccines with the currently existing data, nor to calculate the frequency of appearance of these disorders. However, it is necessary for health professionals to be familiar with these events, facilitating their early diagnosis and treatment. Large controlled epidemiological studies are necessary to establish a possible causal relationship between vaccination against COVID-19 and neurological adverse events.</div></div>","PeriodicalId":19300,"journal":{"name":"Neurologia","volume":"40 1","pages":"Pages 66-76"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33514961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence of cancer in patients with multiple sclerosis (MS) who received rituximab: a systematic review and meta-analysis","authors":"O. Mirmosayyeb ,&nbsp;V. Shaygannejad ,&nbsp;N. Ebrahimi ,&nbsp;H. Ghoshouni ,&nbsp;M. Ghajarzadeh","doi":"10.1016/j.nrl.2022.07.004","DOIUrl":"10.1016/j.nrl.2022.07.004","url":null,"abstract":"<div><h3>Objective</h3><div>To estimate the pooled prevalence of cancer in patients with multiple sclerosis (MS) cases who were under treatment with rituximab.</div></div><div><h3>Methods</h3><div>We searched PubMed, Scopus, EMBASE, Web of Science, and google scholar along with gray literature up to April 2021.</div><div>The search strategy included the MeSH and text words as ((“CD20 Antibody” AND Rituximab) OR “Rituximab CD20 Antibody” OR Mabthera OR “IDEC-C2B8 Antibody” OR “IDEC C2B8 Antibody” OR IDEC-C2B8 OR “IDEC C2B8” OR GP2013 OR Rituxan OR rituximab) AND ((Sclerosis AND multiple) OR (sclerosis AND disseminated) OR \"disseminated sclerosis\" OR \"multiple sclerosis\" OR \"acute fulminating\").</div></div><div><h3>Results</h3><div>The literature search revealed 3577 articles, after deleting duplicates 2066 remained. For the meta-analysis, 22 studies were included. Totally, 15599 patients were enrolled while 133 cancers were detected.</div><div>The pooled prevalence of cancer in MS patients under treatment with rituximab is 1in 100,000 (I2 = 99.9%, p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>The results of this systematic review and meta-analysis show that the pooled prevalence of cancer in MS patients who received rituximab is 1 in 100,000 cases.</div></div>","PeriodicalId":19300,"journal":{"name":"Neurologia","volume":"40 1","pages":"Pages 41-47"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143171399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variant rs4149584 (R92Q) of the TNFRSF1A gene in patients with familial multiple sclerosis","authors":"U. Gomez-Pinedo ,&nbsp;J.A. Matías-Guiu ,&nbsp;L. Torre-Fuentes ,&nbsp;P. Montero-Escribano ,&nbsp;L. Hernández-Lorenzo ,&nbsp;V. Pytel ,&nbsp;P. Maietta ,&nbsp;S. Alvarez ,&nbsp;I. Sanclemente-Alamán ,&nbsp;L. Moreno-Jimenez ,&nbsp;D. Ojeda-Hernandez ,&nbsp;N. Villar-Gómez ,&nbsp;M.S. Benito-Martin ,&nbsp;B. Selma-Calvo ,&nbsp;L. Vidorreta-Ballesteros ,&nbsp;R. Madrid ,&nbsp;J. Matías-Guiu","doi":"10.1016/j.nrl.2022.07.001","DOIUrl":"10.1016/j.nrl.2022.07.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Genomic studies have identified numerous genetic variants associated with susceptibility to multiple sclerosis (MS); however, each one explains only a small percentage of the risk of developing the disease. These variants are located in genes involved in specific pathways, which supports the hypothesis that the risk of developing MS may be linked to alterations in these pathways, rather than in specific genes. We analyzed the role of the <em>TNFRSF1A</em> gene, which encodes one of the TNF-α receptors involved in a signaling pathway previously linked to autoimmune disease.</div></div><div><h3>Methods</h3><div>We included 138 individuals from 23 families including at least 2 members with MS, and analyzed the presence of exonic variants of TNFRSF1A through whole-exome sequencing. We also conducted a functional study to analyze the pathogenic mechanism of variant rs4149584 (-g.6442643C &gt; G, NM_001065.4:c.362 G &gt; A, R92Q) by plasmid transfection into human oligodendroglioma (HOG) cells, which behave like oligodendrocyte lineage cells; protein labeling was used to locate the protein within cells. We also analyzed the ability of transfected HOG cells to proliferate and differentiate into oligodendrocytes.</div></div><div><h3>Results</h3><div>Variant rs4149584 was found in 2 patients with MS (3.85%), one patient with another autoimmune disease (7.6%), and in 5 unaffected individuals (7.46%). The 2 patients with MS and variant rs4149584 were homozygous carriers and belonged to the same family, whereas the remaining individuals presented the variant in heterozygosis. The study of HOG cells transfected with the mutation showed that the protein does not reach the cell membrane, but rather accumulates in the cytoplasm, particularly in the endoplasmic reticulum and near the nucleus; this suggests that, in the cells presenting the mutation, TNFRSF1 does not act as a transmembrane protein, which may alter its signaling pathway. The study of cell proliferation and differentiation found that transfected cells continue to be able to differentiate into oligodendrocytes and are probably still capable of producing myelin, although they present a lower rate of proliferation than wild-type cells.</div></div><div><h3>Conclusions</h3><div>Variant rs4149584 is associated with risk of developing MS. We analyzed its functional role in oligodendrocyte lineage cells and found an association with MS in homozygous carriers. However, the associated molecular alterations do not influence the differentiation into oligodendrocytes; we were therefore unable to confirm whether this variant alone is pathogenic in MS, at least in heterozygosis.</div></div>","PeriodicalId":19300,"journal":{"name":"Neurologia","volume":"40 1","pages":"Pages 10-21"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143171402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Grado de conocimiento de los pacientes con migraña sobre su tratamiento preventivo oral: resultados de un estudio nacional","authors":"A. López-Bravo ,&nbsp;S. Quintas ,&nbsp;A. Mínguez-Olaondo ,&nbsp;A. Alpuente ,&nbsp;C. Nieves-Castellanos ,&nbsp;M. Pilar Navarro-Pérez ,&nbsp;S. Pérez-Pereda ,&nbsp;A. Layos Romero ,&nbsp;C. Calle de Miguel ,&nbsp;D. García-Azorín ,&nbsp;M. Torres-Ferrús ,&nbsp;S. Santos-Lasaosa","doi":"10.1016/j.nrl.2022.11.008","DOIUrl":"10.1016/j.nrl.2022.11.008","url":null,"abstract":"<div><h3>Background</h3><div>Patients’ knowledge about their medications is key to guarantee therapeutic compliance in chronic diseases.</div></div><div><h3>Aims of the Study</h3><div>To determine patients’ knowledge of oral preventive treatment (OPT) in migraine.</div></div><div><h3>Methods</h3><div>This is a cross-sectional study evaluating knowledge of medication with a validated questionnaire that assessed: therapeutic objective, process of use, safety and conservation.</div></div><div><h3>Results</h3><div>198 patients were included. Mean age was 45.4<!--> <!-->±<!--> <!-->11.5 years-old and 92.4% were women. A 61.1% of migraine patients did not know the medication they used, 55.1% showed insufficient knowledge and 6.1% had no knowledge. The most known dimension was “conservation” (80.3%) and the most unknown dimension of was safety (33.7%). In this regard, 82.3% considered that they should not take precautions when taking the treatment, 80.3% stated that it had no contraindications and 82.8% were unaware of possible interactions with other medications. Worse knowledge about OPT was associated with longer time since migraine onset (<em>p</em> <!-->=<!--> <!-->.049), higher scores on the Hospital Anxiety and Depression Scale (<em>p</em> <!-->=<!--> <!-->.021), less qualified jobs (<em>p</em> <!-->=<!--> <!-->.045), use of monotherapy (<em>p</em> <!-->=<!--> <!-->.001) and longer periods since OPT initiation (<em>p</em> <!-->=<!--> <!-->.013).</div></div><div><h3>Conclusions</h3><div>The majority of migraine patients did not adequately know their preventive treatment, despite identifying some of the items related to their medication. The present study shows that knowledge of patients about their preventive treatment should be evaluated in clinical practice and could help migraine patients in the correct use of OPT.</div></div>","PeriodicalId":19300,"journal":{"name":"Neurologia","volume":"40 3","pages":"Pages 249-255"},"PeriodicalIF":2.9,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Síndrome de trombosis con trombocitopenia asociado a vacunas de adenovirus frente a la COVID-19: Epidemiología y presentación clínica de la serie española","authors":"D. García-Azorín ,&nbsp;E. Lázaro ,&nbsp;D. Ezpeleta ,&nbsp;R. Lecumberri ,&nbsp;R. de la Cámara ,&nbsp;M. Castellanos ,&nbsp;C. Iñiguez Martínez ,&nbsp;L. Quiroga-González ,&nbsp;G. Elizondo Rivas ,&nbsp;A. Sancho-López ,&nbsp;P. Rayón Iglesias ,&nbsp;E. Segovia ,&nbsp;C. Mejías ,&nbsp;D. Montero Corominas","doi":"10.1016/j.nrl.2022.04.010","DOIUrl":"10.1016/j.nrl.2022.04.010","url":null,"abstract":"<div><h3>Background</h3><div>We describe the epidemiological and clinical characteristics of thrombosis with thrombocytopenia syndrome (TTS) cases reported in Spain.</div></div><div><h3>Methods</h3><div>We included all venous or arterial thrombosis with thrombocytopenia following adenovirus vector-based vaccines (AstraZeneca or Janssen) to prevent COVID-19 disease between February 1^st and September 26^th, 2021. We describe the crude rate and the standardized morbidity ratio. We assessed the predictors of mortality.</div></div><div><h3>Results</h3><div>Sixty-one cases were reported and 45 fulfilled eligibility criteria, 82% women. The crude TTS rate was 4/1,000,000 doses and 14-15/1,000,000 doses between 30-49 years. The number of observed cases of cerebral venous thrombosis was 6-18 higher than the expected in patients younger than 49 years. Symptoms started 10 (interquartile range [IQR]: 7-14) days after vaccination. Eighty percent (95% confidence interval [CI]: 65-90%) had thrombocytopenia at the time of the emergency department visit, and 65% (95% CI: 49-78%) had D-dimer &gt;2,000 ng/mL. Patients had multiple location thrombosis in 36% and fatal outcome in 24% cases. A platelet nadir &lt; 50,000/μL (odds ratio [OR]: 7.4; CI 95%: 1.2-47.5) and intracranial hemorrhage (OR: 7.9; IC 95%: 1.3-47.0) were associated with fatal outcome.</div></div><div><h3>Conclusion</h3><div>TTS must be suspected in patients with symptoms 10 days after vaccination and thrombocytopenia and/or D-dimer increase.</div></div>","PeriodicalId":19300,"journal":{"name":"Neurologia","volume":"39 9","pages":"Pages 721-732"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10619320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of Bell’s palsy after coronavirus disease (COVID-19) vaccination: a systematic review and meta-analysis","authors":"Atena Soltanzadi ,&nbsp;Omid Mirmosayyeb ,&nbsp;Amin Momeni Moghaddam ,&nbsp;Hamed Ghoshouni ,&nbsp;Mahsa Ghajarzadeh","doi":"10.1016/j.nrl.2022.10.002","DOIUrl":"10.1016/j.nrl.2022.10.002","url":null,"abstract":"<div><h3>Objective</h3><div>To estimate the pooled incidence of Bell’s palsy after COVID-19 vaccination.</div></div><div><h3>Methods</h3><div>PubMed, Scopus, EMBASE, Web of Science, and Google Scholar were searched by 2 independent researchers. We also searched the grey literature including references of the references and conference abstracts. We extracted data regarding the total number of participants, first author, publication year, the country of origin, sex, type of vaccines, and the number of patients who developed Bell’s palsy after COVID-19 vaccination.</div></div><div><h3>Results</h3><div>The literature search revealed 370 articles, subsequently deleting duplicates 227 remained. After careful evaluation of the full texts, 20 articles remained for meta-analysis. The most commonly administered vaccines were Pfizer followed by Moderna.</div><div>In total, 4.54e+07 individuals received vaccines against COVID-19, and 1739 cases developed Bell’s palsy. In nine studies, controls (individuals without vaccination) were enrolled. The total number of controls was 1 809 069, of whom 203 developed Bell’s palsy. The incidence of Bell’s palsy after COVID-19 vaccines was ignorable. The odds of developing Bell’s palsy after COVID-19 vaccines was 1.02 (95% CI: 0.79-1.32) (I2 = 74.8%, <em>P</em> &lt; .001).</div></div><div><h3>Conclusion</h3><div>The results of this systematic review and meta-analysis show that the incidence of peripheral facial palsy after COVID-19 vaccination is ignorable and vaccination does not increase the risk of developing Bell’s palsy. Maybe, Bell’s palsy is a presenting symptom of a more severe form of COVID-19, so clinicians must be aware of this.</div></div>","PeriodicalId":19300,"journal":{"name":"Neurologia","volume":"39 9","pages":"Pages 802-809"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142660391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estudio CORCOBIA: determinación de puntos de corte de biomarcadores de enfermedad de Alzheimer en LCR en una cohorte clínica","authors":"A. Puig-Pijoan ,&nbsp;G. García-Escobar ,&nbsp;A. Fernández-Lebrero ,&nbsp;R.M. Manero Borràs ,&nbsp;G. Sánchez-Benavides ,&nbsp;I. Navalpotro-Gómez ,&nbsp;D. Cascales Lahoz ,&nbsp;M. Suárez-Calvet ,&nbsp;O. Grau-Rivera ,&nbsp;A. Boltes Alandí ,&nbsp;M.C. Pont-Sunyer ,&nbsp;J. Ortiz-Gil ,&nbsp;S. Carrillo-Molina ,&nbsp;D. López-Villegas ,&nbsp;M.T. Abellán-Vidal ,&nbsp;M.I. Martínez-Casamitjana ,&nbsp;J.J. Hernández-Sánchez ,&nbsp;J. Peña-Casanova ,&nbsp;J. Roquer ,&nbsp;A. Padrós Fluvià ,&nbsp;V. Puente-Périz","doi":"10.1016/j.nrl.2022.05.005","DOIUrl":"10.1016/j.nrl.2022.05.005","url":null,"abstract":"<div><h3>Introduction</h3><div>The analysis of the <em>core</em> biomarkers of Alzheimer's disease (AD) in the cerebrospinal fluid (CSF) is recommended in the clinical units where it is available. Because of the absence of universal validated values, the determination of specific cut-off points (COP) for each center and its population is recommended. The main objective of the CORCOBIA study was to determine the COP of <em>core</em> AD CSF biomarkers for several centers (Parc de Salut Mar, Barcelona, and Hospital General de Granollers), which work with the same reference laboratory (Laboratori de Referència de Catalunya).</div></div><div><h3>Methods</h3><div>Prospective study including cognitively healthy subjects (n<!--> <!-->=<!--> <!-->42), subjects with amnestic mild cognitive impairment (n<!--> <!-->=<!--> <!-->35) and patients with dementia due to AD (n<!--> <!-->=<!--> <!-->48), in whom clinical and neuropsychological assessment, neuroimaging, <em>APOE</em> genotyping and lumbar puncture to analyze amyloid beta peptides (Aβ42, Aβ40), total tau (tTau) and phosphorylated Tau (pTau181) using the Lumipulse® G600II (Fujirebio) was performed. The values of sensitivity, specificity, predictive values and area under the curve (AUC) were calculated, determining the COP according to the Youden index by comparing the groups of cognitively healthy subjects and AD.</div></div><div><h3>Results</h3><div>The resulting COP and their AUC were the following: Aβ42 750<!--> <!-->pg/ml (AUC 0.809); Aβ42/Aβ40 0.062<!--> <!-->pg/ml (AUC 0.78); pTau181 69.85<!--> <!-->pg/ml (AUC 0.81); tTau 522.0<!--> <!-->pg/ml (AUC 0.79); Aβ42/tTau 1.76<!--> <!-->pg/ml (AUC 0.86); Aβ42/pTau181 10.25<!--> <!-->pg/ml (AUC 0.86).</div></div><div><h3>Conclusions</h3><div>The determination of COP of <em>core</em> AD CSF biomarkers for the participating centers allows a better diagnostic accuracy. The ratio CSF Aβ42/pTau181 shows the highest AUC and better balance between sensitivity and specificity.</div></div>","PeriodicalId":19300,"journal":{"name":"Neurologia","volume":"39 9","pages":"Pages 756-765"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48847561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validación de Neuromyotype: un teclado inteligente para la evaluación de pacientes con atrofia muscular espinal 5q","authors":"P. Lizandra Cortés ,&nbsp;D. Poveda Verdú ,&nbsp;A. Albert Férriz ,&nbsp;N.C. Ñungo-Garzón ,&nbsp;M.C. Domine ,&nbsp;T. Sevilla-Mantecón ,&nbsp;I. Pitarch-Castellano ,&nbsp;J.F. Vázquez-Costa","doi":"10.1016/j.nrl.2022.05.004","DOIUrl":"10.1016/j.nrl.2022.05.004","url":null,"abstract":"<div><h3>Introduction</h3><div>Spinal muscular atrophy 5q (SMA) is a genetic neurodegenerative disease that affects alpha motor neurons producing progressive weakness. New outcome measures are currently required to accurately characterize the disease progression and the efficacy of new available treatments. The objective of this work is to preliminarily validate a new intelligent keyboard (Neuromyotype) measuring typing strength and speed in patients with SMA.</div></div><div><h3>Material and methods</h3><div>Twenty two SMA patients older than 15<!--> <!-->years, and 26 healthy controls were included. Three measurements were obtained with the keyboard (maximum strength, execution time of a random typing task, execution time of a sequential typing task) together with the time to complete the Nine-Hole Peg Test (9HPT). Patients were also administered motor (Hammersmith Functional Motor Scale Expanded [HFMSE], Revised Upper Limb Module [RULM]), and functional scales (Egen Klassification [EK2] and the revised version of Amyotrophic Lateral Sclerosis Functional Rating Scale [ALSFRS-R]). The viability and construct validity of the Neuromyotype were analyzed, measuring the discriminative power between patients and controls (using ROC curves and the Bangdiwala statistic), between the different functional types of SMA (walker, sitter and non-sitter) and their correlation with the rest of motor scales.</div></div><div><h3>Results</h3><div>Neuromyotype measurements could be performed in all patients, unlike the rest of the scales. Its administration was quick and easy. The 3 variables on the keyboard discriminated very well between patients and controls, with strength (ROC<!--> <!-->=<!--> <!-->0.963) being the one that best differentiates from the 3, equaling 9HPT (ROC<!--> <!-->=<!--> <!-->0.966). They also showed a good ability to differentiate by functional type (especially non-sitters from sitters and walkers), with sequential time (B<!--> <!-->=<!--> <!-->0.83) being the tool that best discriminates between the three groups above the rest of motor scales. All motor and functional scales showed strong or very strong correlations with each other (rs<!--> <!-->=<!--> <!-->0.71-0.99), with strength correlating better with motor scales and timed variables with functional scales.</div></div><div><h3>Conclusion</h3><div>This study shows the feasibility and validity of Neuromyotype for the evaluation of adolescent and adult patients with SMA. Data obtained with this tool could be of great clinical relevance, saving time and resources compared to the rest of the scales.</div></div>","PeriodicalId":19300,"journal":{"name":"Neurologia","volume":"39 9","pages":"Pages 733-742"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44068696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the burden of migraine on the partner’s lifestyle","authors":"E. Fernández-Bermejo ,&nbsp;Á. Planchuelo-Gómez ,&nbsp;S. Quintas ,&nbsp;A. Gonzalez-Martinez ,&nbsp;D. García-Azorín ,&nbsp;Á. Sierra-Mencía ,&nbsp;Á.L. Guerrero ,&nbsp;S. Santos-Lasaosa ,&nbsp;M. Pilar Navarro-Pérez ,&nbsp;N. González-García ,&nbsp;J. Díaz-de-Terán ,&nbsp;A.B. Gago-Veiga","doi":"10.1016/j.nrl.2022.12.003","DOIUrl":"10.1016/j.nrl.2022.12.003","url":null,"abstract":"<div><h3>Background</h3><div>Despite the number of research studies regarding the individual burden of migraine, few studies have examined its impact on the patients’ partners. We aim to assess migraine effects on the patients’ partners on sentimental relationship, children relationship, friendship, and work, as well as the caregiver burden, anxiety and/or depression.</div></div><div><h3>Methods</h3><div>A cross-sectional observational study was conducted through an online survey of partners of patients with migraine followed-up in 5 Headache Units. Questions about the 4 areas of interest and 2 scales (Hospital Anxiety and Depression Scale and Zarit scale) were included. Scores were compared against the population prevalence.</div></div><div><h3>Results</h3><div>One hundred and fifty-five answers were analysed. Among the patient’s partners 135/155 (87.1%) were men, with a mean age of 45.6 ± 10.1 years. Migraine’s main effects on partners were observed in the sentimental relationship and items concerning children and friendships, with a minor impact at work. Partners showed a moderate burden (12/155 = 7.7% [4.1%–13.1%]), and a higher moderate-severe anxiety rate (23/155 = 14.8% [9.6%–21.4%]), and similar depression rate (5/155 = 3.2% [1.1%–7.3%]) compared to the National Health Survey.</div></div><div><h3>Conclusions</h3><div>The burden of migraine impacts the partners’ personal relationship, childcare, friendship and work. Moreover, certain migraine partners showed a moderate burden according to Zarit scale and higher anxiety levels than the Spanish population.</div></div>","PeriodicalId":19300,"journal":{"name":"Neurologia","volume":"39 9","pages":"Pages 810-819"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142660272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fear of Relapse Scale: Spanish version and psychometric characteristics in a sample of patients with Relapsing-Remitting multiple sclerosis","authors":"Y. Broche-Pérez ,&nbsp;R.M. Jiménez-Morales ,&nbsp;L.O. Monasterio-Ramos ,&nbsp;L.A. Vázquez-Gómez ,&nbsp;Z. Fernández-Fleites","doi":"10.1016/j.nrl.2022.06.005","DOIUrl":"10.1016/j.nrl.2022.06.005","url":null,"abstract":"<div><h3>Introduction</h3><div>Relapses are a hallmark of multiple sclerosis, being a characteristic feature of relapsing-remitting multiple sclerosis (RRMS). The occurrence of a relapse constitutes a source of significant discomfort that impacts all domains of daily life of patients with multiple sclerosis (PwMS). In this study we first explored the psychometric properties of the Spanish version of the Fear of Relapse Scale (FoR) in a sample of patients with RRMS. Besides, we explored the relationship between the Fear of Relapse Scale with fatigue and cognitive perceived deficits in our PwMS sample.</div></div><div><h3>Methods</h3><div>An online cross-sectional survey was conducted on 173 MS patients from 12 Spanish-speaking countries (Argentina, Mexico, Uruguay, Dominican Republic, Spain, Cuba, Colombia, Guatemala, Chile, Paraguay, Peru, and El Salvador). Confirmatory factor analysis (CFA) was performed to assess the factor structure of the scale. Multiple linear regression was used to evaluate the effects of health self-perception, fatigue, and perceived cognitive deficits over fear of relapse.</div></div><div><h3>Results</h3><div>The three-factor model in the CFA yielded a good model fit (<em>χ</em>²<em>/df</em> = 2.25, <em>P</em> &lt; .001, RMSEA = .078, CFI = .91). McDonalds’ Omega of the FoR (Spanish version) was .91. There was a statistically significant inverse correlation between FoR and health self-perception, and a positive correlation between FoR, fatigue, and perceived cognitive deficits. Finally, level of fatigue was a predictor of fear of relapse.</div></div><div><h3>Conclusions</h3><div>The Spanish version of the Fear of Relapse Scale is a valid and reliable instrument to explore the experience of fear of relapse in patients with RRMS.</div></div>","PeriodicalId":19300,"journal":{"name":"Neurologia","volume":"39 9","pages":"Pages 749-755"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142660388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}